Ethical Challenges of Bioprinted and Lab-Grown Skin Substitutes in Burn Care

Abstract

Severe burns continue to impose significant global morbidity and mortality, particularly where surgical and critical-care resources are limited. As survival has improved, attention has shifted toward optimizing reconstruction. Bioprinted and lab-grown skin substitutes—building on advances in tissue engineering, cellular scaffolds, and 3D bioprinting—offer new possibilities for coverage, yet raise ethical, legal, and distributive challenges that remain underexamined in burn care. A narrative review was conducted using PubMed, Embase, Web of Science, and Google Scholar (2010-2025), supplemented by foundational legal and bioethics literature. Sources were selected for conceptual and policy relevance to ownership, consent, commercialization, intellectual property (IP), and equity in regenerative skin technologies. Fifty publications spanning burn surgery, biobanking, organoid governance, IP law, and global health were synthesized inductively. Five major ethical domains emerged: (1) ambiguous ownership and ontological status of hybrid bioprinted tissues; (2) inadequacy of consent processes to address commercialization and downstream uses of patient-derived cells; (3) complex IP environments that may restrict access and clinical innovation; (4) distributive injustice driven by high costs and global resource disparities; and (5) a near absence of empirical ethics research involving burn patients or care teams. Bioprinted and lab-grown skin substitutes could transform burn reconstruction, but current ethical and regulatory frameworks lag behind. Addressing ownership, consent, commercialization, and equity—supported by robust empirical engagement with patients—is essential for responsible integration of these technologies into burn care.

Coordination-related ethical challenges in large-scale earthquake response: a cross-sectional survey of field and institutional personnel involved in the 2023 Kahramanmaraş earthquake response, Türkiye
Filiz Turk, Mevlut Karadag, Ismet Sahin
BMC Public Health28 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
Advancing cardiac xenotransplantation: overcoming challenges and ethical considerations for clinical integration.
Ahmed A Abdelrehim, Daniel J Hurst, W Hampton Gray +2
Frontiers in transplantation5 Oct 2026Peer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
Ethical challenges in the clinical translation of anti-amyloid monoclonal antibodies for Alzheimer's disease: a scoping review.
Alexandra Wicker, Amanda Courtright-Lim, Jon Tilburt
Frontiers in psychiatry5 Oct 2026Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine
Sabah Aafreen, Sayed Abdur Rehman, Tahmeed Parvez Barbhuiya +5
Nanomedicine6 Oct 2026Peer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
Ethosomal drug delivery systems for skin cancer: Mechanistic insights, formulation strategies, and translational challenges.
Bhupendra G Prajapati, Omar Awad Alsaidan, Sami I Alzarea +7
BioImpacts : BI9 Aug 2026Peer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{khorsandi2026ethical,
  title = {{Ethical Challenges of Bioprinted and Lab-Grown Skin Substitutes in Burn Care}},
  author = {Joshua Khorsandi and Brian Mansoury and Abu-Bakr Ahmed and Liahm Blank and Michael Harouni and Demitri Franzoni and Joshua MacDavid},
  journal = {Journal of Burn Care \& Research: Official Publication of the American Burn Association},
  year = {2026},
  month = jul,
  doi = {10.1093/jbcr/irag125},
  url = {https://doi.org/10.1093/jbcr/irag125},
  note = {CC BY 4.0},
}

RIS

TY  - JOUR
TI  - Ethical Challenges of Bioprinted and Lab-Grown Skin Substitutes in Burn Care
AU  - Joshua Khorsandi
AU  - Brian Mansoury
AU  - Abu-Bakr Ahmed
AU  - Liahm Blank
AU  - Michael Harouni
AU  - Demitri Franzoni
AU  - Joshua MacDavid
PY  - 2026
DA  - 2026/07/22
JO  - Journal of Burn Care & Research: Official Publication of the American Burn Association
DO  - 10.1093/jbcr/irag125
UR  - https://doi.org/10.1093/jbcr/irag125
AB  - Severe burns continue to impose significant global morbidity and mortality, particularly where surgical and critical-care resources are limited. As survival has improved, attention has shifted toward optimizing reconstruction. Bioprinted and lab-grown skin substitutes—building on advances in tissue engineering, cellular scaffolds, and 3D bioprinting—offer new possibilities for coverage, yet raise ethical, legal, and distributive challenges that remain underexamined in burn care. A narrative review was conducted using PubMed, Embase, Web of Science, and Google Scholar (2010-2025), supplemented by foundational legal and bioethics literature. Sources were selected for conceptual and policy relevance to ownership, consent, commercialization, intellectual property (IP), and equity in regenerative skin technologies. Fifty publications spanning burn surgery, biobanking, organoid governance, IP law, and global health were synthesized inductively. Five major ethical domains emerged: (1) ambiguous ownership and ontological status of hybrid bioprinted tissues; (2) inadequacy of consent processes to address commercialization and downstream uses of patient-derived cells; (3) complex IP environments that may restrict access and clinical innovation; (4) distributive injustice driven by high costs and global resource disparities; and (5) a near absence of empirical ethics research involving burn patients or care teams. Bioprinted and lab-grown skin substitutes could transform burn reconstruction, but current ethical and regulatory frameworks lag behind. Addressing ownership, consent, commercialization, and equity—supported by robust empirical engagement with patients—is essential for responsible integration of these technologies into burn care.
SN  - 1559-047X
SN  - 1559-0488
ER  -

Abstract

Related

Cite